搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Epidermal growth factor Like Domain Protein, Multiple 7 (EGFL7) ELISA Kit

Human Epidermal growth factor Like Domain Protein, Multiple 7 (EGFL7) ELISA Kit

  • 中文名稱：
    人表皮生長因子樣結(jié)構(gòu)域蛋白7(EGFL7)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E15864h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人表皮生長因子樣結(jié)構(gòu)域蛋白7(EGFL7)酶聯(lián)免疫試劑盒（CSB-E15864h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿樣本中的EGFL7含量。EGFL7 即表皮生長因子樣蛋白 7，在血管發(fā)育、腫瘤血管生成等過程中發(fā)揮重要作用。研究表明，它可調(diào)節(jié)內(nèi)皮細胞遷移、增殖和血管管腔形成。其異常表達與腫瘤進展、轉(zhuǎn)移相關(guān)，有望成為腫瘤診斷和治療的新靶點，為腫瘤防治帶來新思路。試劑盒檢測范圍為0.47 μg/mL-30 μg/mL，該產(chǎn)品適用于體外實驗研究，例如探究心血管疾病、腫瘤生物學或組織修復過程中EGFL7的動態(tài)變化，亦可用于評估不同實驗條件下（如藥物處理、基因編輯）該蛋白的表達調(diào)控機制。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    EGF like domain 7 ELISA Kit; EGF like domain containing protein 7 ELISA Kit; EGF like domain multiple 7 ELISA Kit; EGF-like protein 7 ELISA Kit; EGFL 7 ELISA Kit; EGFL7 ELISA Kit; EGFL7_HUMAN ELISA Kit; Epidermal growth factor like domain protein 7 ELISA Kit; Epidermal growth factor-like protein 7 ELISA Kit; MEGF 7 ELISA Kit; MEGF7 ELISA Kit; MGC111117 ELISA Kit; Multiple EGF like domain protein 7 ELISA Kit; Multiple EGF-like domains protein 7 ELISA Kit; Multiple epidermal growth factor like domain protein 7 ELISA Kit; Multiple epidermal growth factor-like domains protein 7 ELISA Kit; NEU1 ELISA Kit; NEU1 protein ELISA Kit; NOTCH4 like protein ELISA Kit; NOTCH4-like protein ELISA Kit; RP11 251M1.2 ELISA Kit; UNQ187/PRO1449 ELISA Kit; Vascular endothelial statin ELISA Kit; VE statin ELISA Kit; VE-statin ELISA Kit; ZNEU 1 ELISA Kit; ZNEU1 ELISA Kit
  • 縮寫：
    EGFL7
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    0.47 μg/mL-30 μg/mL
  • 靈敏度：
    0.12 μg/mL
  • 反應時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cardiovascular
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human EGFL7 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:1 Average % 95  
    Range % 90-102  
    1:2 Average % 95  
    Range % 83-101  
    1:4 Average % 96  
    Range % 90-106  
    1:8 Average % 94  
    Range % 82-101  
  • 回收率：
    The recovery of human EGFL7 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 92 85-98  
    EDTA plasma (n=4) 94 91-100  
                 
                 
  • 標準曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    μg/ml OD1 OD2 Average Corrected  
    30 2.753 2.618 2.686 2.572  
    15 2.421 2.404 2.413 2.299  
    7.5 1.894 1.877 1.886 1.772  
    3.75 1.186 1.197 1.192 1.078  
    1.87 0.610 0.634 0.622 0.508  
    0.94 0.411 0.407 0.409 0.295  
    0.47 0.265 0.271 0.268 0.154  
    0 0.112 0.115 0.114 　  
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點詳情

  • 功能：
    Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.
  • 基因功能參考文獻：
    1. Data show that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was much higher than that of non-invasive GHPA. PMID: 29951953
    2. EGFL7 was found to be a potential predictor for HCC survival and metastasis state. PMID: 29970668
    3. Levels of both EGFL7 mRNA and EGFL7 protein are increased in blasts of patients with acute myeloid leukemia (AML) compared with normal bone marrow cells. High EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) and younger (age <60 y) patients with cytogenetically normal AML. PMID: 28533390
    4. In conclusion, miR-126 could inhibit tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression PMID: 27611944
    5. This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer PMID: 28275117
    6. Oncogenic activation of EGFRwt in GBM is likely maintained by a continuous EGFL7 autocrine flow line. PMID: 27725228
    7. Egfl7 is thus an endogenous and constitutive repressor of blood vessel endothelial cell activation in normal and inflammatory conditions and participates in a loop of regulation of activation of these cells by pro-inflammatory cytokines. PMID: 27650497
    8. Up-regulated MALAT1 promoted the invasion and metastasis of GC, and the increase of EGFL7 expression was a potential mechanism via altering its H3 histone acetylation level PMID: 27259812
    9. These findings suggest that the stimulating effect of EGFL7-ESCs on fibroblast proliferation and migration may provide a useful strategy for wound healing. PMID: 27766530
    10. A gene expression study was conducted to investigate the levels of Egfl7 and miRNA126-5p in human carotid artery atherosclerotic plaques PMID: 26799121
    11. By regulating endothelial cell adhesion, EGFL7 plays a key role in the regulation of glioma angiogenesis. PMID: 26722408
    12. The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase. PMID: 26542361
    13. EGFR mutational analysis is useful in the diagnosis of non-small-cell-lung cancer. PMID: 26288231
    14. The aim of the present descriptive study was to analyse the intra-tumoural expressions of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126 (miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer. PMID: 25592646
    15. EGFL7, OPN, and PGE2 may have a role in recurrence and metastasis of hepatocellular carcinoma PMID: 25730089
    16. High EGFL7 expression promotes migration and Epithelial-Mesenchymal Transition in pancreatic Cancer. PMID: 25987088
    17. Loss of EGFL7 expression is associated with Malignant Pleural Mesothelioma. PMID: 26504055
    18. Data suggest that, in trophoblast cells, EGFL7 regulates cell migration and invasion/placentation by activating multiple signaling pathways via MAPK, PI3K (phosphatidylinositol 3-kinase), and NOTCH1 (translocation-associated notch protein 1). PMID: 25667199
    19. EGFL7 may predict response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer PMID: 25140000
    20. Endothelial cells control pancreatic cell fate at defined stages through EGFL7 signaling. PMID: 25601205
    21. EGFL7 enhances EGFR-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PMID: 24945379
    22. demonstrate significantly reduced Egfl7 expression in pre-eclampsia placentas, concurrent with a downregulation of Notch target genes PMID: 24751645
    23. The loss of EGFL7 expression play a role in the development and progression of systemic sclerosis. PMID: 24286167
    24. egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries. PMID: 24595089
    25. EGFL7 promotes growth of Renal cell carcinoma by facilitating migration and tube formation of endothelial cells. These effects were produced by EGFL7-mediated focal adhesion kinase phosphorylation through combination with epidermal growth factor receptor. PMID: 24815445
    26. malignant glioma cells and glioma vascular endothelial cells highly express VE-statin/Egfl7, which is significantly correlated with the degree of malignancy. PMID: 24696719
    27. Egfl7 is significantly upregulated in human epithelial tumor tissues, suggesting Egfl7 to be a potential biomarker for human epithelial tumors, especially liver and breast cancer. PMID: 23558933
    28. study provides clinical data indicating a relationship between miRNA-126 and the clinical outcome of metastatic colorectal cancer patients treated with chemotherapy combined with anti-VEGF-A, whereas the impact of EGFL7 is more speculative PMID: 23922111
    29. Early-onset intrauterine growth restriction at 20-24 weeks' gestation is associated with higher values of EGFL7 expression in maternal plasma. PMID: 23280513
    30. Egfl7 expression is thus associated with better prognosis factors and with the absence of lymph node invasion in human breast cancer lesions. PMID: 23404186
    31. Data indicate that EGFL7 and integrin alphavbeta3 integrin colocalized in vesicular structures in uman umbilical vein endothelial cells (HUVECs). PMID: 23386126
    32. Two angiogenesis-associated transcripts (Egfl7 and Acvrl1) showed lower expression in early-onset PE versus late-onset pre-eclampsia and versus gestational age-matched controls. PMID: 22013081
    33. Human breast cancer lesions expressing high levels of Egfl7. PMID: 22037871
    34. Studies indicate that Egfl7 controls blood vessel development by promoting endothelial cell migration and proliferation. PMID: 22160377
    35. Heterogeneous methylation in the promoter region of EGFL7 was associated with cancer progression in non-small cell lung cancer. PMID: 22018271
    36. miR-126 can downregulate EGFL7 expression at the protein level in ECV-304 cells. PMID: 20423846
    37. Studies indicate that two biologically active miRNAs miR-126 and its complement miR-126*, which are encoded by intron 7 of the egfl7 gene, have been described to mediate vascular functions. PMID: 20953557
    38. EGFL7 may be used as a predictive marker for glioma prognosis and as a potential therapeutic target for malignant glioma. PMID: 20213100
    39. Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. PMID: 20837907
    40. miR-126 can inhibit proliferation of non-small cell lung cancer cells through one of its targets, EGFL7. PMID: 20034472
    41. is the first identified inhibitor of mural cell migration specifically produced by endothelial cells. PMID: 14592969
    42. Human EGFL7 may protect endothelial cell from hyperoxia-induced apoptosis by inhibition of mitochondria-dependent apoptosis pathway. PMID: 17934064
    43. Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype. PMID: 18193184
    44. The lack of association between expression of miRNA and its host gene EGFL7 suggests their regulation by independent stimuli in colon cancer. PMID: 18521848
    45. Mature miR-126 can be generated from three different transcripts of EGFL7 with each one having its own promoter. PMID: 19116145
    46. Egfl7 promotes metastasis of hepatocellular carcinoma (HCC) by enhancing cell motility through EGFR-dependent FAK phosphorylation. PMID: 19824075

    顯示更多

    收起更多

  • 亞細胞定位：
    Secreted, extracellular space.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 20594

    OMIM: 608582

    KEGG: hsa:51162

    STRING: 9606.ENSP00000307843

    UniGene: Hs.91481